Pfizer Halts Hemophilia B Gene Therapy

In a surprising development, Pfizer has discontinued Beqvez™, their hemophilia B gene therapy, despite FDA approval just last spring. The company cited “limited interest” from patients and providers as a key factor. This highlights the complex considerations surrounding gene therapy adoption, including long-term efficacy concerns and cost. NBDF’s Gene Therapy Resource Guide and shared decision-making materials remain available to help navigate treatment options.